by Clinical Neuropsychologist | Tuesday, June 18, 2024 | Dementia
Abstract INTRODUCTION Corticobasal syndrome (CBS) can result from underlying Alzheimer’s disease (AD) pathologies. Little is known about the utility of blood plasma metrics to predict positron emission tomography (PET) biomarker-confirmed AD in CBS. METHODS A...
by Clinical Neuropsychologist | Monday, June 17, 2024 | Dementia
Abstract INTRODUCTION Tau aggregation into neurofibrillary tangles in Alzheimer’s disease (AD) is a dynamic process involving changes in tau phosphorylation, isoform composition, and morphology. To facilitate studies of tangle maturity, we developed an image...
by Clinical Neuropsychologist | Monday, June 17, 2024 | Dementia
Abstract INTRODUCTION Intraneuronal inclusions composed of tau protein are found in Alzheimer’s disease (AD) and other tauopathies. Tau normally binds microtubules (MTs), and its disengagement from MTs and misfolding in AD is thought to result in MT...
by Clinical Neuropsychologist | Monday, June 17, 2024 | Dementia
Abstract Cerebral amyloid angiopathy (CAA) is characterized by the accumulation of amyloid protein in the walls of cerebral blood vessels. This deposition of amyloid causes damage to the cerebral vasculature, resulting in blood-brain barrier disruption, cerebral...
by Clinical Neuropsychologist | Saturday, June 15, 2024 | Dementia
Abstract INTRODUCTION TAR DNA-binding protein 43 (TDP-43) is a highly prevalent proteinopathy that is involved in neurodegenerative processes, including axonal damage. To date, no ante mortem biomarkers exist for TDP-43, and few studies have directly assessed its...
